New Zealand markets open in 9 hours 33 minutes

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.01-0.69 (-1.83%)
At close: 04:00PM EDT
36.92 -0.09 (-0.24%)
Pre-market: 07:52AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close37.70
Bid36.86 x 900
Ask36.92 x 1100
Day's range36.45 - 37.15
52-week range26.19 - 49.07
Avg. volume663,624
Market cap24.168B
Beta (5Y monthly)0.64
PE ratio (TTM)72.57
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

    Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

  • Zacks

    Should You Buy Genmab (GMAB) Ahead of Earnings?

    Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Zacks

    Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study

    Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.